Showing results (1191-1200 of 1,350) with videos related to
Sort By:
Pageof 135
The European Journal of Neuroscience|August 26, 2011
Nav 1.1 dysfunction in genetic epilepsy with febrile seizures-plus or Dravet syndromeLinda Volkers, Kristopher M Kahlig, Nienke E Verbeek, et al.Journal of the American College of Cardiology|November 20, 2012
Vagal reflexes following an exercise stress test: a simple clinical tool for gene-specific risk stratification in the long QT syndromeLia Crotti, Carla Spazzolini, Alessandra P Porretta, et al.Human Molecular Genetics|December 16, 2010
Amniocytes can serve a dual function as a source of iPS cells and feeder layersRaymond M Anchan, Philipp Quaas, Behzad Gerami-Naini, et al.Cell Transplantation|November 26, 2013
Propagation of human corneal endothelial cells: a novel dual media approachGary S L Peh, Zhenzhi Chng, Heng-Pei Ang, et al.The Oncologist|February 12, 2017
Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) TrialsXiaofei Wang, Xiaoyi Wang, Lydia Hodgson, et al.Free Radical Biology & Medicine|November 23, 2025
Mutant p53 disrupts antioxidant defense in fallopian tube epithelium via GSTAs suppression: A pathway to serous tubal carcinogenesisDestiny B Burnett, Sandy St-Hilaire, Leah Dodds, et al.Biorxiv : the Preprint Server for Biology|June 4, 2026
Excitatory Dysfunction and Phenotypic Rescue in a Human Neuronal Model of <i>SCN2A</i> -Related DisordersSashmita Panda, Diana Jazmin Ixmatlahua Ribera, Luis A Williams, et al.Blood|July 27, 2001
Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabineR M Stone, D T Berg, S L George, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2002
Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420Sherif S Farag, Stephen L George, Edward J Lee, et al.Science Advances|September 15, 2016
Structural basis for KCNE3 modulation of potassium recycling in epitheliaBrett M Kroncke, Wade D Van Horn, Jarrod Smith, et al.Pageof 135